Brief: Telix Pharmaceuticals Says TLX101-PX (PIXLUMI®) MAA Accepted In Europe
01/05/2026 02:15
May 1 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX: TLX101-PX (PIXLUMI®) MAA ACCEPTED IN EUROPE TLX101-TX GRANTED ORPHAN DRUG DESIGNATION IN EUROPE AND U.S. Further company coverage: TLX.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Telix Pharmaceuticals
See all newsMorningstar says shares of Australia's Telix Pharmaceuticals undervalued
Australia's Telix in focus as Citi signals confidence in prostate cancer drug
Brief: Telix Announces Collaborations To Explore Psma-Pet Imaging In Emerging Prostate Cancer Treatment Approaches
Australia's Telix gains as Europe accepts brain cancer imaging therapy marketing application
Brief: Telix Pharmaceuticals Says TLX101-PX (PIXLUMI®) MAA Accepted In Europe